Updates

ITE - International expansion underway

January 2014

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

ITE has reported its full results with revenues up 12% to £192m and pretax profit up 12% to £59.4m in its stronger biennial year. Adjusted eps lifted 14% to 19.3p. Net cash at the year end was £23.5m. The Russian business has, of course, been the main story here. Stripping out the biennial events Russia went up 10% like-for-like to £121m sales and within that, the mainstay, which are the Moscow events were up 7% like-for-like. In Russia, some 109 events were held, says chief executive Russell Taylor but the top four or five grew a bit less than in previous years with most of the growth coming in the mid tier events and more from local rather than international exhibitors. That said, Moscow saw a decent enough performance from the ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Alliance Pharma

CSR

ITE - Russia down to 50% and 43% of FY15 and FY16 forecasts (April 2015)

ITE (November 2014)

ITE (June 2014)

ITE - Forecasts downgraded after annexation of Crimea (May 2014)

ITE (December 2013)

ITE (September 2013)

ITE - Targeting event aquisitions in Malaysia (June 2013)

ITE (February 2013)

ITE (January 2013)

ITE (June 2012)

ITE (May 2012)

ITE (February 2012)

ITE - Russian events business on a roll (January 2012)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X